CONGRESS PRESENTATIONS

HIV Drug Therapy Glasgow 2024

Glasgow, Scotland
November 10-13, 2024

HIV Glasgow 2024 Bibliography

2024 Post Fall Conference - ViiV Medical Webinar

Wednesday, November 20, 2024
6:00 - 7:15 PM ET

Explore an interactive view of ViiV-sponsored data presented at the HIV Glasgow Congress on November 11th.

  • ViiV-Sponsored Data

    Cabotegravir Prevention

    Cabotegravir Treatment

    Dolutegravir-based Regimens

    Fostemsavir

    Pipeline

    Other Disease-Related Content

    This content was acquired following an unsolicited medical information enquiry by a healthcare professional.  Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license.  In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.

  • ViiV-Supported & Collaborative Data

    Cabotegravir Prevention

    Jonas K, et al.

    Intention to use long‐acting PrEP among 4960 heterosexual women and men in 20 European countries: results from the PROTECT survey

    Wang H, et al.

    Differences in oral PrEP use patterns and intention to use long-acting regimens among MSM between formal and informal PrEP provision pathways in 20 European countries: a latent class analysis

    Zimmermann H, et al.

    Preparing for long‐acting PrEP delivery: provider preferences for the provision of long‐acting PrEP differ between MSM and heterosexual individuals in Europe

    Cabotegravir Treatment

    Cabello A, et al.

    Feasibility and satisfaction of interventions measures (FIM and HIVTISQ) of implementation long‐acting (LA) CAB+RPV administration out of HIV units: the IMADART study

    Elias A, et al.

    Re‐suppression regimens and outcomes after virological failure in randomized controlled trials and real‐world evidence studies evaluating cabotegravir and rilpivirine (CAB+RPV)

    Fernández A, et al.

    Cabotegravir and rilpivirine concentrations and HIV-1 RNA suppression in male and female genital fluids and rectal tissue in people with HIV on antiretroviral therapy with long-acting intramuscular cabotegravir plus rilpivirin

    Hessamfar M, et al.

    Use of long‐acting cabotegravir and rilpivirine in a real‐life setting: 12‐month results of virological outcome, adherence, safety, durability, in the ANRS CO3 AquiVIH‐NA Cohort‐France

    Hidalgo‐Tenorio C, et al.

    Results at month 7 of CABO‐CHANCE study: real‐world evidence (RWE) on the use of intramuscular cabotegravir plus rilpivirine long‐acting (CAB+RPV LA) dosed every 2 months in viral suppressed people with HIV (PWH)

    Smuk M, et al.

    Virological failure rate and emergent resistance in real‐world studies evaluating long‐acting cabotegravir and rilpivirine in people with baseline viral suppression

    Dolutegravir-based Regimens

    Cordova E, et al.

    Efficacy of dolutegravir plus lamivudine in treatment‐naïve people living with HIV without baseline drug‐resistance testing available: 48‐week results from the randomised D2ARLING study

    de Lagarde Sebastian M, et al.

    Long‐term efficacy and safety of dolutegravir/lamivudine in virologically suppressed persons with HIV and history of resistance to lamivudine: week 96 results of VOLVER clinical trial ‐ GESIDA 11820

    Degroote S, et al.

    RUMBA's week 144 results confirm reassuring metabolic outcomes in both DTG/3TC and B/FTC/TAF

    Figueroa MI, et al.

    Comparable efficacy and safety of dolutegravir/lamivudine to a three drug regimen amongst ARV naive people living with HIV with CD4 <200/mm3: the DOLCE study

    Garcia‐Fraile L, et al.

    Changes in patient‐reported neuropsychological outcomes in virologically suppressed persons with HIV switching to DTG/3TC or BIC/FTC/TAF: a substudy of the PASO‐DOBLE randomized clinical trial

    Miro JA, et al.

    Efficacy and safety of dolutegravir (DTG)‐based antiretroviral treatment (ART) in patients with HIV and solid organ transplantation (SOT): a single‐arm clinical trial (DTG‐SOT)

    Ryan R, et al.

    Dolutegravir‐based antiretroviral therapy does not reduce plasma levonorgestrel or medroxyprogesterone acetate concentrations among contraceptive users living with HIV compared with HIV‐negative controls

    Voit F, et al.

    Evaluating the cardiovascular risk and the achievement of target levels in low‐density lipoprotein cholesterol in PLWH: insights from the DUALIS study

    Wolf E, et al.

    Mental health in people with HIV (PWH): patient‐reported outcomes in the DUALIS study

    Other Disease-Related Content

    Allavena C, et al.

    Comparison of four frailty scores to predict adverse health outcomes and mortality in people living with HIV aged 70 years and more (ANRS EP66 SEPTAVIH study)

    Deb S, et al.

    The association between anticholinergic medication use and cognitive function in older people with HIV in the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study

    Sukumaran L, et al.

    The prevalence and factors associated with polypharmacy in participants with HIV in the Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study over a 3‐5 year period

    This content was acquired following an unsolicited medical information enquiry by a healthcare professional.  Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their license.  In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.

Are you a US healthcare provider?

This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.

Connect With Our Medical Experts

Find My ViiV MSL

Easily find the ViiV Medical Science Liaison (MSL) in your area.

Request a Scientific Discussion

Submit a request for additional information from a ViiV Medical Expert.

Contact Us

Chat Live

Get immediate assistance from a ViiV Healthcare Professional.

Call 1‑888‑226‑8434

Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)

Report an Adverse Event

To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1‑877‑844‑8872 or FDA at 1‑800‑332‑1088 or www.fda.gov/medwatch